Healthcare stocks were edging higher premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) slightly advancing and the iShares Biotechnology ETF (IBB) up 0.5%.
Sionna Therapeutics (SION) shares fell more than 89% after the company said it will not advance SION-719 as an add-on therapy to standard of care Trikafta in cystic fibrosis patients after a phase 2a proof-of-concept failed to meet its key activity endpoint of sweat chloride reduction.
AbCellera Biologics' (ABCL) ABCL635 met the primary efficacy endpoints in the phase 2 portion of a Phase 1/2 study, significantly lowering the frequency and severity of moderate-to-severe hot flashes versus placebo, the company said. AbCellera Biologics stock was up more than 33% pre-bell.
Axsome Therapeutics (AXSM) shares were up more than 2% after the company posted a higher Q2 revenue.